Wallace Eli M. — SEC Form 4 filings

SEC reporting owner CIK 1776352. 4 Form 4 filings on record with FilingPulse; latest filed 2026-01-05.

Transaction summary — filings shown

Covers all 4 filings on record, filed 2025-08-28 to 2026-01-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
BridgeBio Oncology Therapeutics, Inc. (BBOT)Chief Executive Officer, Director44

Form 4 filings — Wallace Eli M.

FiledFormIssuerReported transactionsSource
2026-01-054BridgeBio Oncology Therapeutics, Inc. (BBOT)Grant/award (A): 1,114,400 (derivative) @ $0EDGAR
2025-12-124BridgeBio Oncology Therapeutics, Inc. (BBOT)Disposition to issuer (D): 1,114,400 (derivative)EDGAR
2025-10-064BridgeBio Oncology Therapeutics, Inc. (BBOT)Grant/award (A): 1,614,400 (derivative) @ $0EDGAR
2025-08-284BridgeBio Oncology Therapeutics, Inc. (BBOT)Grant/award (A): 499,731 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1776352 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →